Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2009 August;144(4) > Giornale Italiano di Dermatologia e Venereologia 2009 August;144(4):333-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

  PEMPHIGUS AND PEMPHIGOID UPDATE IN 2009


Giornale Italiano di Dermatologia e Venereologia 2009 August;144(4):333-8

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Treatment of bullous pemphigoid and pemphigus. The French experience, 2009 update

Roujeau J. C. 1, 3, Ingen-Housz-Oro S. 1, 3, Leroux C. 1, 4, Joly P. 2, 5

1 Ile de France Reference Center on “toxic” and Auto-Immune Blistering Diseases, Henri Mondor Hospital, Paris XII University, Créteil, France 2 National Reference Center on Auto-Immune Blistering Diseases, Paris, France 3 Hôpital Henri Mondor, Créteil, France 4 Hôpital Avicenne, Bobigny, France 5 Hôpital Charles Nicolle, Rouen, France


PDF  


There have been several recent advances in the management of auto-immune blistering diseases. The aim of this review was to provide an update, based on “expert” interpretation of published evidences on the treatments of pemphigoid and pemphigus. A literature search (Pubmed) of all randomized controlled trials that had not been included in two reviews published by the Cochrane Skin Group in 2005 on pemphigoid and 2009 on pemphigus have been performed. Recent series of pemphigus cases treated with anti-CD20 antibodies have also been reviewed. Concerning pemphigoid there is good evidence that high dose topical clobetasol propionate should be the first line treatment, and that further studies should focus on the finding of simple and well tolerated maintenance therapy. For pemphigus, after decades of inconclusive trials, there is now some evidence of a moderate efficacy of azathioprine, cyclophosphamide, mycophenolate in addition to corticosteroids and may be of intravenous immunoglobulins. The practical impact of such evidence is strongly challenged by the possible superiority of anti-CD20 monoclonal antibodies that may emerge as the most efficient treatment of pemphigus. Because of concerns on long-term safety, multicenter trials of these “biological” treatments should be undertaken urgently.

top of page

Publication History

Cite this article as

Corresponding author e-mail